S2 Ep29: Celltrion Breaks New Ground With a Subcutaneous Biosimilar Infliximab - a podcast by Not So Different: a Podcast from The Center for Biosimilars
from 2019-12-08T06:00
::
::
Last month, the European Commission authorized a subcutaneously administered formulation of biosimilar infliximab CT-P13 for the treatment of rheumatoid arthritis. When the drug launches in the European Union, it will be first infliximab to be available in a subcutaneous formulation. This week on the podcast, we’re speaking about this new product with Mike An, head of the sales and operations division at Celltrion Healthcare.
Further episodes of Not So Different: a Podcast from The Center for Biosimilars
Further podcasts by Not So Different: a Podcast from The Center for Biosimilars
Website of Not So Different: a Podcast from The Center for Biosimilars